VEA
ADCT icon

Virtus ETF Advisers’s ADC Therapeutics ADCT Stock Holding History

Virtus ETF Advisers’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,193
Closed -$282K – 436
2022
Q1 		$282K Hold
19,193
– – 0.13% 179
2021
Q4 		$388K Sell
19,193
-535
-3% -$12.9K 0.15% 161
2021
Q3 		$536K Sell
19,728
-1,812
-8% -$46.4K 0.24% 128
2021
Q2 		$524K Buy
21,540
+12,764
+145% +$296K 0.22% 133
2021
Q1 		$214K Buy
8,776
+160
+2% +$4.63K 0.09% 315
2020
Q4 		$276K Buy
+8,616
New +$282K 0.11% 260

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $901M AUM 28.6% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Virtus ETF Advisers's ADCT Position: Q2 2022 in Review

Virtus ETF Advisers sold out of ADC Therapeutics (ADCT) in Q2 2022, closing a stake of 19,193 shares — an estimated $282K sold.

Virtus ETF Advisers first reported a position in ADCT in Q4 2020 and held it in 6 quarters. The position peaked at $536K in Q3 2021. 58 funds tracked by Wall St. Rank hold ADCT as of Q2 2022.

  • Virtus ETF Advisers reported no remaining ADC Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Virtus ETF Advisers sold 19,193 ADC Therapeutics shares in Q2 2022, an estimated $282K.
  • Virtus ETF Advisers first reported a position in ADC Therapeutics in Q4 2020 and held it in 6 quarters.
  • Virtus ETF Advisers's ADC Therapeutics position peaked at $536K in Q3 2021.
  • 58 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.